Search Results - linda+wyatt

14 Results Sort By:
A Novel Virus-Based Expression System
The present invention is related to a recombinant viral vector for vaccines. Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response. The present novel virus-based expression vectors...
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): Expression, Gene, GENES, High, LOW, Non-Replicating, System, TARGET, vaccinia, Vector, virus, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WIXXXX, WNXXXX, XEXXXX, YAXXXX, YBXXXX, YFXXXX
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics
Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines
The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of...
Published: 7/25/2024   |   Inventor(s): Patricia Earl, Linda Wyatt, Bernard Moss
Keywords(s): ANKARA, Del, Expression, Fied, Foreign, GB1DXX, GB1XXX, GBXXXX, Gene, GENES, GXXXXX, INCREASE, Insertion, LIl, Modi, Modified, MVA, Patent Category - Biotechnology, PLASMID, SHUTTLE, SITE, STABILITY, vaccinia, Vector, virus
Category(s): Collaboration Sought > Licensing, Application > Therapeutics
Biological/Research Material for HIV Vaccine Research
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines. Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated...
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): 239gagpol, ACXXXX, AXXXXX, DC5XXX, DCXXXX, DXXXXX, EXPRESSES, Gene, MVA/SIV239gagpol, MVNSIV239gagpoi, PJH4, recombinant, RESEARCH MATERIAL, SIV, SIV239gagpol, That, virus
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines
Biological/Research Material for H1N1 Influenza Virus Vaccine Research
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice. The materials can be used for research purposes and in particular in the area of influenza virus...
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): A/PR/8/34, Attenuated, AXXXXX, DCXXXX, DDXXXX, DXXXXX, EXPRESSES, H1N1, Ha, Haemagglutinin, INFLUENZA, MVA, Np, NUCLEOPROTEIN, RESEARCH MATERIAL, That, vaccinia, virus
Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease
A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes
Since the onset of the AIDS epidemic more than two decades ago, enormous efforts have been directed to making a vaccine that will protect against human immunodeficiency virus-1 (HIV); an effective vaccine is thought to require the induction of cellular and humoral responses. Vaccine candidates have included a variety of HIV immunogens delivered as...
Published: 7/25/2024   |   Inventor(s): Patricia Earl, Linda Wyatt, Bernard Moss
Keywords(s): Alteration, Alternation, BETWEEN, Clinical, CODON, Constructs, DC5AXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Enhanced, ESSENTIAL, Foreign, Gene, Genebetween, GENES, Hyper IgM syndrome, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, Insertion, Inserts, Mechanism, MVA/HIV1, PLASMID, recombinant, Severe combined immunodeficiency, x-linked, SHUTTLE, STABILITY, TWO, Vaccine, vaccinia, virus, Wiskott Aldrich syndrome
Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Vaccines
Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development
The current technology relates to the construction, characterization and immunogenicity of modified vaccinia Ankara (MVA) recombinant viruses. The MVA double recombinant viruses express modified/truncated HIV-1 Env and mutated HIV Gag Pol under the control of vaccinia virus early/late promoters. This technology describes the MVA double recombinant...
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): 47 XYY syndrome, DC5AXX, DCXXXX, Double Y, DXXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines
MVA Expressing Modified HIV envelope, gag, and pol Genes
This invention claims Modified Vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing Human Immunodeficiency Virus (HIV) env, gag, and pol genes, where the genes are isolated from Ugandan Clade D isolates, Kenyan Clade A isolates, and Tanzanian Clade C isolates. In a rhesus macaque SHIV model, DNA priming followed by a...
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Patricia Earl, Bernard Moss
Keywords(s): (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, Altered, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, D, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, Envelope, Expressing, G syndrome, GAG, GENES, HAD deficiency, HIS deficiency, Histidinemia, HIV, Hyper IgM syndrome, Hypertelorism with esophageal abnormality and hypospadias, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, MVA, N syndrome, polymerase, R(6) syndrome, R(7) syndrome, Severe combined immunodeficiency, x-linked, Subtype, Syndrome X, W syndrome, W syndrome; Syndrome W, Wiskott Aldrich syndrome
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines
pLAS-1 Plasmid
Shuttle vector for construction of recombinant MVA viruses.
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): Biological, Construction, E-023-2003, LVD, Material:, MVA, pLAS1, pLAS-1, recombinant, RM, SHUTTLE, Vector, Viruses, VLXXXX, WIXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials
Self-neutralizing air-breathing thruster and method of neutralization
An ion-engine is the cutting edge for atmospheric air-breathing engines. The technology depends on ionizing and neutralizing atmospheric air particles which create thrust. This unique possibility makes it an ideal choice for very-low-orbit satellites. Very- low-orbit satellite capabilities have benefits such as higher resolution for images, weight...
Published: 7/30/2024   |   Inventor(s): Michael Keidar, Anmol Taploo, Li Lin
Keywords(s):  
Category(s): Technology Classifications > Computers Electronics & Software, Technology Classifications > Computers Electronics & Software > Aviation, Technology Classifications > Industrial or Consumer Tech > Energy Infrastructure and Environment, Technology Classifications > Industrial or Consumer Tech > Industrial Manufacturing
Non-Invasive Plasma Discharge Tube Device for Treating Brain Tumors
Treating brain tumors, like glioblastoma, is challenging. Current glioblastoma drugs, Rapamycin and Temozolomide (TMZ), generally only extend life for a matter of months, are not very effective in treating recurring tumors, and have significant clinical toxicity. A novel Plasma Discharge Tube (PDT) device has the potential to be more effective and less...
Published: 7/30/2024   |   Inventor(s): Michael Keidar, Li Lin, Vikas Soni, Xiaoliang Yao, Dayun Yan, Jonathan Sherman
Keywords(s):  
Category(s): Technology Classifications > Medical Devices, Technology Classifications > Medical Devices > Surgical
1 2